Patents Assigned to FELICITEX THERAPEUTICS, INC.
  • Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
    Patent number: 11202779
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: December 21, 2021
    Assignee: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases
    Patent number: 10577365
    Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 3, 2020
    Assignees: Felicitex Therapeutics, Inc., Selvita S.A.
    Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
  • Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
    Patent number: 10322128
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 18, 2019
    Assignee: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
    Patent number: 10314843
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 11, 2019
    Assignee: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES
    Publication number: 20180179199
    Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 20, 2017
    Publication date: June 28, 2018
    Applicants: Felicitex Therapeutics, Inc., Selvita S.A.
    Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS
    Publication number: 20170296542
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
    Type: Application
    Filed: April 14, 2017
    Publication date: October 19, 2017
    Applicant: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS
    Publication number: 20170296541
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 19, 2017
    Applicant: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • TREATMENT OF CANCER BY TARGETING QUIESCENT CANCER CELLS
    Publication number: 20150292032
    Abstract: A method for treating a subject suffering from a neoplasm, comprising determining the expression level of a DYRK1 selected from DYRK1A or DYRK1B within a cell population in a sample of neoplastic cells and determining the quiescent state of these cells, and if the DYRK1 is expressed in the sample then administering an effective amount of a modulator of DYRK1 activity, either alone or as a part of a combination therapy.
    Type: Application
    Filed: October 10, 2013
    Publication date: October 15, 2015
    Applicant: FELICITEX THERAPEUTICS, INC.
    Inventors: Maria Vilenchik, Michael Frid, Yuri Gankin